Comparison of Rosaramicin and Erythromycin Stearate for Treatment of Cervical Infection with Chlamydia trachomatis

Robson, Hugh G.; Shah, Pramod P.; Lalonde, Richard; Hayes, Linda J.; Senikas, Vyta

doi:10.1097/00007435-198307000-00006

Sexually Transmitted Diseases

1983

DOI: 10.1097/00007435-198307000-00006

|View full text |Cite

Comparison of Rosaramicin and Erythromycin Stearate for Treatment of Cervical Infection with Chlamydia trachomatis

Hugh G. Robson¹,

Pramod P. Shah²,

Richard Lalonde³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1986

1994

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 10 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like erythromycin, dirithromycin is concentrated intracellularly (3). Erythromycin and other macrolides have been shown to have both in vitro and in vivo activity against Chlamydia trachomatis (1,4,5,7). However, there is no published information on the activity of dirithromycin against C. trachomatis.…”

mentioning

confidence: 99%

In vitro activity of dirithromycin against Chlamydia trachomatis

Segreti

Kapell

1994

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Dirithromycin is a new macrolide antibiotic with an active metabolite, erythromycylamine. We evaluated the in vitro activities of both drugs against 16 isolates of Chiamydia trachomatis and compared them with that of doxycycline. In vitro susceptibility testing was performed with McCoy cell monolayers. The MIC was defined as the lowest concentration of antibiotic without inclusions. The MBC was defined as the lowest concentration of antibiotic yielding no inclusions after passage onto 24-h-old antibiotic-free McCoy cell monolayers. Dirithromycin and erythromycylamine appeared to be equally effective against these 16 strains of C. trachomatis (MIC for 90%o of strains tested, mg/ml; MBC for 90% of strains tested, 2 p,g/ml). Both were less active than doxycycline (MIC for 90%o of strains tested, 0.06 ,g/ml; MBC for 90%o of strains tested, 0.12 ,ug/ml). The combination of dirithromycin and erythromycylamine appeared to be additive.Dirithromycin is a new macrolide antibiotic which is metabolized to an active compound, erythromycylamine (2). It has in vitro activity comparable to that of erythromycin (9). Like erythromycin, dirithromycin is concentrated intracellularly (3). Erythromycin and other macrolides have been shown to have both in vitro and in vivo activity against Chlamydia trachomatis (1, 4, 5, 7). However, there is no published information on the activity of dirithromycin against C. trachomatis. Therefore, we tested the in vitro activities of dirithromycin and erythromycylamine against clinical isolates of C. trachomatis and compared them with that of doxycycline, an antibiotic commonly used to treat C. trachomatis infections. We also tested dirithromycin and erythromycylamine for synergy.Dirithromycin and erythromycylamine were obtained from Lilly Pharmaceuticals (Indianapolis, Ind.), and doxycycline was obtained from Sigma Chemicals (St. Louis, Mo.). These drugs were prepared as stock dilutions in concentrations of 1,280 ,ug/ml according to their stated potencies. Stock solutions were stored at -70°C for a maximum of 2 weeks. Drugs were diluted to the appropriate concentration with medium containing Hanks' balanced salt solution, amino acids, vitamins, 1% glutamine, 10% inactivated fetal calf serum, 5.4 g of glucose per liter, and 1 ,ug of cycloheximide per ml. Dilutions were made on the day of use. A total of 16 strains of C. trachomatis, including one serotype D strain (ATCC VR-885), one lymphogranuloma venereum type 2 strain (ATCC VR-902b), and 14 clinical isolates, were tested. All clinical isolates were of genital origin and had been passed fewer than 10 times in the laboratory. All isolates were passed an additional two times in antibiotic-free medium before susceptibility testing and were stored at -70°C until the time of use.The antimicrobial susceptibility of C. trachomatis was determined by using 96-well dilution plates as previously described (6). McCoy cell monolayers, 24-h old and grown in antibioticfree medium, were inoculated with a dilution of C. trachomatis test strain known to yield 500 ...

show abstract

mentioning

confidence: 99%

In vitro activity of dirithromycin against Chlamydia trachomatis

Segreti

Kapell

1994

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Treatment of Sexually Transmitted Chlamydial Infections

Sanders¹

1986

JAMA

View full text Add to dashboard Cite

Tetracycline hydrochloride, 500 mg orally four times a day for seven days, remains the treatment of choice for C trachomatis infections in men and nonpregnant women. Either erythromycin, 500 mg orally four times daily for seven days, or an equivalent dosage of another erythromycin product is an alternative treatment for patients who cannot tolerate tetracycline and for pregnant women. These two treatment regimens can be generalized to include nongonococcal urethritis and mucopurulent cervicitis. However, other treatment regimens that are effective against C trachomatis may not be effective for treating nongonococcal urethritis or mucopurulent cervicitis not caused by C trachomatis. The optimal treatment for pregnant women with C trachomatis infections and women with acute PID has not been established. Additional treatment trials with both groups of patients are needed to determine the effectiveness of antimicrobial agents in addition to those currently used, to establish the appropriate dose of each antimicrobial agent, and to clarify the appropriate duration of treatment. All individuals who are sexual partners of patients with nongonococcal urethritis, mucopurulent cervicitis, and acute PID (within the 30 days prior to onset of their symptoms or time of positive clinical evaluation findings) should be examined for sexually transmitted disease and treated promptly with a regimen effective against uncomplicated gonorrhea and chlamydial infections. Prompt treatment of sexual partners reduces the rate of treatment failure due to reinfection, reduces the transmission of infection, and reduces the frequency of occurrence of adverse sequelae of infection.

show abstract

Comparative efficacy of clindamYcin versus erythromycin in eradication of antenatal Chlamydia trachomatis

Alger

1991

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comparison of Rosaramicin and Erythromycin Stearate for Treatment of Cervical Infection with Chlamydia trachomatis

Cited by 10 publications

References 0 publications

In vitro activity of dirithromycin against Chlamydia trachomatis

In vitro activity of dirithromycin against Chlamydia trachomatis

Treatment of Sexually Transmitted Chlamydial Infections

Comparative efficacy of clindamYcin versus erythromycin in eradication of antenatal Chlamydia trachomatis

Contact Info

Product

Resources

About